Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 12,680 matching trials from the live ClinicalTrials.gov search.
Conditions
Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions
PXS-5505
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas
Completed Not applicable Interventional Results available

A Novel Strategy to Decrease Fall Incidence Post-Stroke

NCT02688777
Conditions
Stroke
Interventions
Backward Walking Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 90 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

NCT05043766
Conditions
Healthy Volunteers
Interventions
PF614, Naltrexone Hydrochloride, OxyContin
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522
Conditions
End Stage Renal Disease, Renal Impairment
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Placebo (blinded), LX9211 (blinded)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Conditions
Healthy
Interventions
Nemtabrutinib, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Shoulder Pain
Interventions
Eccentric Strengthening, Traditional Strengthening, Pain education
Procedure · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Photosensitive Epilepsy
Interventions
Placebo, E2730
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Boise, Idaho • Baltimore, Maryland + 2 more
Conditions
Refractive Errors
Interventions
Lotrafilcon A contact lenses, Balafilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
1,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
San Diego, California • Jacksonville, Florida • Miami, Florida + 5 more
Conditions
Hypertension
Interventions
Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

NCT00986401
Conditions
Healthy
Interventions
Trospium Chloride (Sanctura XR®), Metformin hydrochloride (Glucophage®)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Atrial Fibrillation, Cardiovascular Diseases, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes
Interventions
Insertable Cardiac Monitor or external non-invasive LT-ECG patch
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, New York
Completed No phase listed Observational Accepts healthy volunteers

Using Hydration Monitor to Detect Changes in the Hydration Status Athletes

NCT02206581
Conditions
Dehydration
Interventions
Hydration Monitor
Device
Lead sponsor
Artann Laboratories
Industry
Eligibility
18 Years to 25 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boone, North Carolina
Conditions
Intracerebral Hemorrhage
Interventions
Excel Cryo Cooling System
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Refractive Errors
Interventions
LID018869+RepleniSH, LID018869+Biotrue, Biofinity+RepleniSH, PV+Biotrue
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Maitland, Florida
Conditions
Glioblastoma
Interventions
Sirolimus, Vandetanib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Acute Coronary Syndrome, Physical Inactivity
Interventions
Positive Psychology + Motivational Interviewing
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lymphedema, Lymphedema of Leg, Chronic Venous Insufficiency, Venous Insufficiency, Lymphedema, Lower Limb
Interventions
Cross over Device (PCD or Dayspring - alternate to first group)
Device
Lead sponsor
Koya Medical, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Oakland, California
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

NCT05672927
Conditions
Immunization, HPV Infection, Human Papillomavirus
Interventions
9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
27 Years to 45 Years · Female only
Enrollment
618 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Cystinosis
Interventions
Cystagon® (Cysteamine Bitartrate), Cysteamine Bitartrate Delayed-release Capsules (RP103)
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois
Completed Not applicable Interventional Results available

Interpretation Modification Program for Social Phobia

NCT00684541
Conditions
Social Anxiety Disorder, Social Phobia
Interventions
Interpretation Modification Program, Interpretation Control Condition
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Diego, California
Conditions
Papillomavirus Infections
Interventions
9vHPV vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 26 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
14
States / cities
Daly City, California • Oakland, California • Roseville, California + 10 more